title: Second-line Antiretroviral Treatment in Resource-Limited Settings: Abandon Lopinavir/Ritonavir Monotherapy or Search for New Candidates?
authors.affiliation: Department of Infectious Disease, The Second Affiliated Hospital of Medical School of the Southeast University, Nanjing.
authors.forename: Zhiliang
authors.initials: Z
authors.lastname: Hu
authors.affiliation: Department of Infectious Disease, Beijing You'an Hospital, Capital Medical University, China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of Infectious Disease, The Second Affiliated Hospital of Medical School of the Southeast University, Nanjing.
authors.forename: Yongfeng
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Infectious Disease, The Second Affiliated Hospital of Medical School of the Southeast University, Nanjing.
authors.forename: Hongxia
authors.initials: H
authors.lastname: Wei
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D061466:Lopinavir / Q000627:therapeutic use*; D008297:Male; D019438:Ritonavir / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D061466:Lopinavir; D019438:Ritonavir